These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1038 related items for PubMed ID: 18073016

  • 1. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B.
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [Abstract] [Full Text] [Related]

  • 2. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S.
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [Abstract] [Full Text] [Related]

  • 3. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubó J, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D, STOPAR Study Team.
    Antivir Ther; 2012 Jan; 17(3):577-83. PubMed ID: 22301439
    [Abstract] [Full Text] [Related]

  • 4. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J, HIV-NAT 013 Study Team.
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF, Swiss HIV Cohort Study.
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [Abstract] [Full Text] [Related]

  • 7. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J, Souyris C, Sandres-Sauné K, Puissant B, Obadia M, Pasquier C, Puel J, Blancher A, Massip P.
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J, Marchou B, Charreau I, Sauné K, Tangre P, Molina JM, Aboulker JP, Window (ANRS 106) Study Team.
    Antivir Ther; 2008 Nov; 13(4):537-45. PubMed ID: 18672532
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P.
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Mar; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 18. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D, ANRS 116 SALTO Study Group.
    J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
    [Abstract] [Full Text] [Related]

  • 19. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
    Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M, Woodfall B.
    Antivir Ther; 2009 Nov; 14(5):713-22. PubMed ID: 19704175
    [Abstract] [Full Text] [Related]

  • 20. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
    De Felipe B, Blanco A, Soriano-Sarabia N, Muñoz-Fernández MA, Genebat M, Vallejo A, Leal M.
    Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.